1 / 11

Nathan Mendes Ronnie Ng Scott Perkins Zvi Rhine Zack Weaver

Symbol: MRK Exchange: NYSE 12/4/2000. Nathan Mendes Ronnie Ng Scott Perkins Zvi Rhine Zack Weaver. Profile.

kane-alston
Download Presentation

Nathan Mendes Ronnie Ng Scott Perkins Zvi Rhine Zack Weaver

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Symbol: MRK Exchange: NYSE 12/4/2000 • Nathan Mendes • Ronnie Ng • Scott Perkins • Zvi Rhine • Zack Weaver

  2. Profile • Merck & Co., Inc. is a global, research-driven pharmaceutical company that discovers, develops, manufactures and markets a broad range of human and animal health products, directly and through its joint ventures and provides pharmaceutical benefit services through Merck-Medco Managed Care.

  3. Major Drugs • Zocor & Mevacor: Cholesterol Drugs • Vasotec, Cozaar & Hyzaar: Hypertension and Heart Failure • Fosamax: Osteoporosis • Pepcid: Anti-ulcerant • M-M-R II & Varivax- Live Vaccines • Singulair: Asthma • Crixivan & Strocrin: HIV Symptom Treatment • Aggrastat: Prevents Blood Clots • Vioxx: Arthritis

  4. Expiring Patents • 2000 • Pepcid • Vasotec • 2001 • Mevacor • Prinvil • Combined 1999 Domestic Sales of $3 Billion • Mevacor and Vasotec already being phased out

  5. Growth Opportunities Vioxx • Relief of osteoarthritis and acute pain • Inhibits Cox-2 enzyme while protecting Cox-1 • Relieves pain while easy on the stomach • More than 5 milion prescriptions in the first seven months on the U.S. market • Once daily dosage- ease of use • Competitive boost in efficient launch of Vioxx • Patients were able to start taking the drug within days of its approval

  6. Growth Opportunities Zocor • Lowers bad cholesterol levels and triglycerides while raising levels of good cholesterol (HDL) • Money back guarantees if patients cannot reach their cholesterol goals • Number 1 cholesterol lowering drug in the European market • U.S. Market has room to grow • Only 4 out of 10 heart disease patients with dangerous cholesterol levels use a cholesterol lowering drug

  7. Growth Opportunities Singulair • Asthma medication • Number of children with asthma has increased 160% since 1980 Fosamax • Osteoporosis • Only drug consistently proven to increase bone density • Shows results within 12-18 months of first dose • significantly shorter than most drugs

  8. One Year Performance • Up 23.4% from date purchased

  9. Industry • S&P Pharmaceuticals are up 22.5% (Year to October 6) • S&P 1500 is -2.7% (Year to October 6) • Concerns over pricing restraints over new Medicare prescription plans • Income and Price Inelasticity of Drugs is favorable • FDA is streamlining and making more efficient new drug approval processes • Kick-ass margins • Upwards of 20%

  10. Competitors

  11. Recommendation HOLD

More Related